The latest data released by UnitedHealthcare in the United States shows that its pulmonary arterial hypertension treatment drug Tyvaso demonstrates good tolerability, and the drug’s safety profile remains consistent with previous clinical trial results.

Research results show that Tyvaso maintained stable safety characteristics during long-term use, with no new safety signals observed. The efficacy of this drug in improving patients' exercise tolerance is consistent with known data, providing a sustained and effective treatment option for patients with pulmonary arterial hypertension. This data further consolidates Tyvaso's position in the field of pulmonary arterial hypertension treatment, and its consistent safety profile offers clinicians and patients a more reliable basis for medication use.